Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-KLK2 CAR T cells JNJ-75229414

A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting human kallikrein-2 (hK2; KLK2) expressed on tumor cells, with potential immunostimulating and antineoplastic activities. Upon administration, anti-KLK2 CAR T cells JNJ-75229414 target and bind to KLK2-expressing tumor cells, thereby inducing selective toxicity in KLK2-expressing tumor cells. KLK2 is overexpressed in certain tumors, including prostate adenocarcinoma.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-kallikrein-2 CAR T cells JNJ-75229414 KLK2 CAR-T cells JNJ-75229414
Code name:	JNJ 75229414 JNJ-75229414 JNJ75229414

anti-KLK2 CAR T cells JNJ-75229414

Search NCI's Drug Dictionary